See every side of every news story
Published loading...Updated

Tirzepatide Reduces Obesity-Associated Breast Cancer Growth in Mouse Model

SAN FRANCISCO COUNTY, CALIFORNIA, JUL 12 – The anti-obesity drug tirzepatide reduced body weight and tumor volume by about 20% in mice, suggesting potential to improve obesity-linked breast cancer outcomes, researchers said.

Summary by Medical Xpress
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

7 Articles

Six weeks ago I started injecting myself with tirzepatide, one of the new fashion weight-loss drugs. The results so far are excellent: I dropped 10 kilos, I have more energy, I get tired less and sleep better. But in all these days, especially on Tuesday nights, when I have to put the syringe together and stick it in my belly, I couldn’t stop thinking about the novelty of all this, whether I’m cheating on biology or the “power of will” and what …

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Saturday, July 12, 2025.
Sources are mostly out of (0)